By Maria Kalamatas | The Logistic News | April 1, 2025
In a significant move to bolster its presence in the pharmaceutical logistics sector, DHL Group has announced the acquisition of CRYOPDP, a leading specialty courier renowned for its expertise in clinical trials, biopharmaceuticals, and cell and gene therapies.
Expanding DHL’s Life Sciences and Healthcare Portfolio
DHL’s Life Sciences and Healthcare division, which reported revenues exceeding €5 billion in 2024, stands to gain substantially from this acquisition. By integrating CRYOPDP’s specialized services, DHL aims to offer more comprehensive supply chain solutions tailored to the complex demands of the healthcare industry.
Formation of a Strategic Partnership
In conjunction with the acquisition, DHL and Cryoport, CRYOPDP’s parent company, have agreed to establish a strategic partnership. This collaboration is designed to strengthen both entities’ supply chain service offerings within the global life sciences and healthcare sector, fostering innovation and enhancing service delivery.
Regulatory Approvals and Future Outlook
The completion of the acquisition and the implementation of the strategic partnership are subject to regulatory approvals. Once finalized, these initiatives are expected to significantly bolster DHL’s capabilities in managing temperature-sensitive shipments, ensuring the safe and efficient transportation of critical healthcare products worldwide.
Maria Kalamatas is a senior correspondent for The Logistic News, specializing in mergers and acquisitions within the logistics and transportation industries.
